IIIM-290
CAS No. 2213468-64-3
IIIM-290( IIIM290 )
Catalog No. M13528 CAS No. 2213468-64-3
IIIM-290 is a potent, orally active cyclin-dependent kinase (CDK) inhiitor with IC50 of 1.9 and 16 nM for Cdk-9/T1 and Cdk-2/A, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 1143 | Get Quote |
|
| 50MG | 2322 | Get Quote |
|
| 100MG | 3060 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameIIIM-290
-
NoteResearch use only, not for human use.
-
Brief DescriptionIIIM-290 is a potent, orally active cyclin-dependent kinase (CDK) inhiitor with IC50 of 1.9 and 16 nM for Cdk-9/T1 and Cdk-2/A, respectively.
-
DescriptionIIIM-290 is a potent, orally active cyclin-dependent kinase (CDK) inhiitor with IC50 of 1.9 and 16 nM for Cdk-9/T1 and Cdk-2/A, respectively; selectively inhibits Molt-4/MIAPaCa-2 cell growth with GI50 of <1 uM; inhibits the cell growth of MIAPaCa-2 cells via caspase-dependent apoptosis, demonstrates in vivo efficacy in pancreatic, colon, and leukemia xenografts at 50 mg/kg, po., without CYP/efflux-pump liability, and mutagenic/genotoxic or cardiotoxic effects.
-
In Vitro——
-
In Vivo——
-
SynonymsIIIM290
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2213468-64-3
-
Formula Weight462.323
-
Molecular FormulaC23H21Cl2NO5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC1=C2C(OC(/C=C/C3=C(Cl)C=CC=C3Cl)=CC2=O)=C([C@]4([H])[C@H](O)CN(C)CC4)C(O)=C1
-
Chemical Name(1'R,2'S)-2-(2,6-Dichlorostyryl)-5,7-dihydroxy-8-(3-hydroxy-1- methylpiperidin-4-yl)-4H-chromen-4-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bharate SB, et al. J Med Chem. 2018 Feb 22;61(4):1664-1687.
molnova catalog
related products
-
ON123300
ON123300 is a potent, multi-targeted kinase inhibitor with IC50 of 5, 3.9, 26, 26, 9.2 and 11 nM for ARK5, CDK4, PDGFRβ, FGFR1, RET and FYN, respectively.
-
Senexin-A
A selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively.
-
CCT-251921
A potent, selective, and orally bioavailable inhibitor of CDK8 and CDK19 with IC50of 2.3 nM and 2.6 nM respectively.
Cart
sales@molnova.com